Research programme: regulatory T cell-inducing DNA vaccines - Inovio Pharmaceuticals

Drug Profile

Research programme: regulatory T cell-inducing DNA vaccines - Inovio Pharmaceuticals

Latest Information Update: 20 May 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medical Center of Fudan University
  • Developer Inovio Pharmaceuticals
  • Class DNA vaccines
  • Mechanism of Action Immunosuppressants; Regulatory T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Alzheimer's disease; Multiple sclerosis

Most Recent Events

  • 20 May 2014 Inovio Pharmaceuticals acquires worldwide rights (except China) of regulatory T cells inducing DNA vaccine from Medical Center of Fudan University
  • 20 May 2014 Preclinical trials in Alzheimer's disease in USA (unspecified route)
  • 20 May 2014 Preclinical trials in Multiple sclerosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top